Differential Effector Engagement by Oncogenic KRAS.

Cell Rep 2018 02;22(7):1889-1902

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 3rd Street, San Francisco, CA 94158, USA; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., P.O. Box B, Frederick, MD 21702, USA. Electronic address:

KRAS can bind numerous effector proteins, which activate different downstream signaling events. The best known are RAF, phosphatidylinositide (PI)-3' kinase, and RalGDS families, but many additional direct and indirect effectors have been reported. We have assessed how these effectors contribute to several major phenotypes in a quantitative way, using an arrayed combinatorial siRNA screen in which we knocked down 41 KRAS effectors nodes in 92 cell lines. We show that every cell line has a unique combination of effector dependencies, but in spite of this heterogeneity, we were able to identify two major subtypes of KRAS mutant cancers of the lung, pancreas, and large intestine, which reflect different KRAS effector engagement and opportunities for therapeutic intervention.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.01.051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343826PMC
February 2018
54 Reads

Publication Analysis

Top Keywords

effector engagement
8
kras
5
contribute major
4
effectors contribute
4
kras mutant
4
subtypes kras
4
major subtypes
4
phenotypes quantitative
4
assessed effectors
4
major phenotypes
4
effectors reported
4
additional direct
4
effector dependencies
4
families additional
4
direct indirect
4
indirect effectors
4
quantitative arrayed
4
mutant cancers
4
reported assessed
4
identify major
4

Similar Publications